Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 5/2011

01.05.2011 | 2010 SSAT Plenary Presentation

The Duration of Symptoms Predicts the Presence of Malignancy in 210 Resected Cases of Pancreatic Intraductal Papillary Mucinous Neoplasms

verfasst von: Toshiyuki Moriya, Yasushi Hashimoto, L. William Traverso

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Using Kaplan–Meier curves, a 2006 study illustrated a shorter time interval between development of symptoms and detection of malignant IPMN in the main pancreatic duct versus a side-branch duct location. Of 93 cases, only 62 were confirmed histologically. To support these interesting findings, we examined a larger cohort of cases where the diagnosis was confirmed histologically and asked if symptoms by themselves, as well as main duct location, were associated with malignant detection.

Methods

Between 1989 and 2009, 210 IPMN cases meeting international criteria were resected and histologically examined. Actuarial rates of malignant detection over time were calculated from the first clinical symptom to malignant detection (resection). These rates of malignant detection over time were compared for main vs. side-branch duct location and symptomatic vs. asymptomatic cases.

Results

The most common indications for resection were symptoms (88%) and main pancreatic duct location (65%). The actuarial malignant detection rates were significantly shorter for main duct location and also for symptomatic cases, regardless of duct location.

Conclusions

Presence of symptoms followed by main pancreatic duct location had a significantly shorter elapsed time to malignant detection. The visual depiction of these actuarial rates highlights the importance of the clinical history. To determine malignant risk, the primary determinants for resection were either symptoms or main duct location (but not cyst size), confirming the 2006 study with a larger cohort of histologically confirmed cases.
Literatur
1.
Zurück zum Zitat Shyr YM, Su CH, Tsay SH, Lui WY. Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Ann Surg 1996;223:141–146.PubMedCrossRef Shyr YM, Su CH, Tsay SH, Lui WY. Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Ann Surg 1996;223:141–146.PubMedCrossRef
2.
Zurück zum Zitat Traverso LW, Kozarek RA. Diagnosis and Natural History of Intraductal Papillary Mucinous Neoplasms. In Beger HG, Büchler MW, Kozarek RA, Lerch MM, Neoptolemos JP, Shiratori K, Warshaw AL, Whitcomb DC, Rau BM, eds. The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery, 2nd Ed. Malden, MA: Blackwell Publishing, 2008:918–923. Traverso LW, Kozarek RA. Diagnosis and Natural History of Intraductal Papillary Mucinous Neoplasms. In Beger HG, Büchler MW, Kozarek RA, Lerch MM, Neoptolemos JP, Shiratori K, Warshaw AL, Whitcomb DC, Rau BM, eds. The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery, 2nd Ed. Malden, MA: Blackwell Publishing, 2008:918–923.
3.
Zurück zum Zitat Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17–32.PubMedCrossRef Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17–32.PubMedCrossRef
4.
Zurück zum Zitat Levy P, Jouannaud V, O’Toole D, Couvelard A, Vullierme MP, Palazzo L, Aubert A, Ponsot P, Sauvanet A, Maire F, Hentic O, Hammel P, Ruszniewski P. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol 2006;4:460–468.PubMedCrossRef Levy P, Jouannaud V, O’Toole D, Couvelard A, Vullierme MP, Palazzo L, Aubert A, Ponsot P, Sauvanet A, Maire F, Hentic O, Hammel P, Ruszniewski P. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol 2006;4:460–468.PubMedCrossRef
5.
Zurück zum Zitat Terris B, Ponsot P, Paye F, Hammel P, Sauvanet A, Molas G, Bernades P, Belghiti J, Ruszniewski P, Flejou JF. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000;24:1372–1377.PubMedCrossRef Terris B, Ponsot P, Paye F, Hammel P, Sauvanet A, Molas G, Bernades P, Belghiti J, Ruszniewski P, Flejou JF. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000;24:1372–1377.PubMedCrossRef
6.
Zurück zum Zitat Zamboni G, Scarpa A, Bogina G, Iacono C, Bassi C, Talamini G, Sessa F, Capella C, Solcia E, Rickaert F, Mariuzzi GM, Klöppel G. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999;23:410–422.PubMedCrossRef Zamboni G, Scarpa A, Bogina G, Iacono C, Bassi C, Talamini G, Sessa F, Capella C, Solcia E, Rickaert F, Mariuzzi GM, Klöppel G. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999;23:410–422.PubMedCrossRef
7.
Zurück zum Zitat Longnecker DS, Adler G, Hruban RH, Klöppel G. Intraductal papillary-mucinous neoplasms of the pancreas. In Hamilton SR, Aaltonen LA (eds): World Health Organization classification of tumours. Pathology and genetics. Tumours of the digestive system. Lyon, France: IARC Press, 2000, pp 237–241. Longnecker DS, Adler G, Hruban RH, Klöppel G. Intraductal papillary-mucinous neoplasms of the pancreas. In Hamilton SR, Aaltonen LA (eds): World Health Organization classification of tumours. Pathology and genetics. Tumours of the digestive system. Lyon, France: IARC Press, 2000, pp 237–241.
8.
Zurück zum Zitat Klöppel G, Solcia, E, Longnecker DS, Capella C, Sobin LH. World Health Organization international classification of tumours. Histological typing of tumours of the exocrine pancreas. Germany: Springer-Verlag Berlin Heidelberg, 1996, pp 1–61. Klöppel G, Solcia, E, Longnecker DS, Capella C, Sobin LH. World Health Organization international classification of tumours. Histological typing of tumours of the exocrine pancreas. Germany: Springer-Verlag Berlin Heidelberg, 1996, pp 1–61.
9.
Zurück zum Zitat Klöppel G, Luttges J. WHO-classification 2000: exocrine pancreatic tumors. Verh Dtsch Ges Pathol 2001;85:219–228.PubMed Klöppel G, Luttges J. WHO-classification 2000: exocrine pancreatic tumors. Verh Dtsch Ges Pathol 2001;85:219–228.PubMed
10.
Zurück zum Zitat Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg 2007;246:644–651.PubMedCrossRef Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg 2007;246:644–651.PubMedCrossRef
Metadaten
Titel
The Duration of Symptoms Predicts the Presence of Malignancy in 210 Resected Cases of Pancreatic Intraductal Papillary Mucinous Neoplasms
verfasst von
Toshiyuki Moriya
Yasushi Hashimoto
L. William Traverso
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 5/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-011-1437-6

Weitere Artikel der Ausgabe 5/2011

Journal of Gastrointestinal Surgery 5/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.